20.22
Sarepta Therapeutics Inc stock is traded at $20.22, with a volume of 9.54M.
It is up +0.80% in the last 24 hours and up +48.51% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$20.06
Open:
$20.13
24h Volume:
9.54M
Relative Volume:
0.87
Market Cap:
$1.98B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-7.5167
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-7.29%
1M Performance:
+48.51%
6M Performance:
-80.97%
1Y Performance:
-85.70%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SRPT
Sarepta Therapeutics Inc
|
20.22 | 2.05B | 2.23B | -248.39M | -697.55M | -2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-29-25 | Initiated | Bernstein | Mkt Perform |
Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-24-25 | Initiated | Citigroup | Sell |
Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
Jul-21-25 | Downgrade | Needham | Hold → Underperform |
Jul-21-25 | Downgrade | UBS | Buy → Neutral |
Jul-18-25 | Downgrade | Needham | Buy → Hold |
Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-11-25 | Initiated | Wells Fargo | Overweight |
Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Feb-11-25 | Initiated | Deutsche Bank | Hold |
Nov-27-24 | Reiterated | Needham | Buy |
Nov-25-24 | Initiated | H.C. Wainwright | Sell |
Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Oct-21-24 | Initiated | Jefferies | Buy |
Oct-10-24 | Resumed | Raymond James | Outperform |
Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
May-31-24 | Initiated | Piper Sandler | Overweight |
May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Dec-13-23 | Resumed | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-21-23 | Initiated | Wedbush | Outperform |
Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-26-23 | Initiated | SMBC Nikko | Outperform |
Apr-04-23 | Initiated | Citigroup | Buy |
Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-22-22 | Reiterated | BTIG Research | Buy |
Dec-16-22 | Upgrade | UBS | Neutral → Buy |
Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Jan-05-22 | Reiterated | Needham | Buy |
Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
Jun-15-21 | Initiated | BTIG Research | Buy |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-11-21 | Downgrade | UBS | Buy → Neutral |
Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-11-20 | Initiated | Berenberg | Hold |
Oct-28-20 | Initiated | UBS | Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-31-20 | Initiated | Mizuho | Buy |
Nov-01-19 | Initiated | Guggenheim | Buy |
Aug-21-19 | Reiterated | Needham | Buy |
Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-11-19 | Reiterated | Credit Suisse | Outperform |
Oct-12-18 | Initiated | Bernstein | Outperform |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
Sep-14-18 | Resumed | BofA/Merrill | Buy |
Sep-06-18 | Initiated | Credit Suisse | Outperform |
Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
Jun-20-18 | Reiterated | Needham | Buy |
Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" - Yahoo Finance
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
2025-08-20 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
SRPT Investors Have the Opportunity to Lead the Sarepta - GlobeNewswire
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating - MarketScreener
What MACD and RSI say about Sarepta Therapeutics Inc.Profit Target & Risk Controlled Swing Alerts - Newser
Will Sarepta Therapeutics Inc. bounce back from current supportWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - Barchart.com
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Earnings visualization tools for Sarepta Therapeutics Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser
Burned by Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
SRPT’s Stock Dilemma: Sarepta Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders - GlobeNewswire
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System - Defense World
PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Sarepta Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders - GlobeNewswire
Contact The Gross Law Firm by August 25, 2025 Deadline to - GlobeNewswire
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - Yahoo Finance
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff - GlobeNewswire
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile
Investors In Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
SRPT LOSSES: Sarepta Therapeutics, Inc. Investors with Losses are Encouraged to Contact BFA Law before Expiration of August 25 Class Action Deadline - Newsfile
How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve - Bloomberg.com
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP - GlobeNewswire
Will Sarepta Therapeutics Inc. outperform the marketPortfolio Update Summary & Pattern Based Trade Signal System - Newser
Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC - Defense World
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with - GlobeNewswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities LawsuitContact the DJS Law Group Before the Final DeadlineSRPT - MarketScreener
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
2025-08-17 | Securities Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Represents Shareholders | NDAQ:SRPT | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - Defense World
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
Sarepta Therapeutics and the Biotech Litigation Landscape: Navigating Risk in a High-Stakes Sector - AInvest
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
BFA Law Notifies SAREPTA THERAPEUTICS, INC. (SRPT) Investors to Contact the Firm before the Upcoming August 25 Securities Fraud Class Action Deadline - Newsfile
US Bancorp DE Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop - GlobeNewswire
Sarepta Therapeutics Faces Questions Over Its Key Gene Therapy - Finimize
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sarepta Therapeutics Inc Stock (SRPT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Barry Richard | Director |
May 16 '25 |
Option Exercise |
32.63 |
12,350 |
402,981 |
2,966,667 |
Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):